Trial Profile
A phase I study of the combination of daily oral pazopanib with intravenous ifosfamide in patients with advanced solid malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Ifosfamide (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Acronyms Pazi
- 16 Nov 2015 Status changed from recruiting to completed.
- 06 Nov 2009 New trial record